Haemonetics Corp. (HAE) Tops Q4 EPS by 2c, Announces Buyback Plan and Posts FY12 Guidance
Haemonetics Corp. (NYSE: HAE) reported Q4 adjusted EPS of $0.85, $0.02 better than the analyst estimate of $0.83. Revenue for the quarter came in at $170 million versus the consensus estimate of $180.31 million.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.